{"id":"0cc70c320470","type":"article","url":"https://hartvaat.nl/2026/05/26/odyssey-outcomes-post-hoc-hscrp-en-il-6-zijn-complementaire-prognostische-marker/","title":"ODYSSEY-OUTCOMES post-hoc: hsCRP en IL-6 zijn complementaire prognostische markers na ACS","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag317","source_url":"https://doi.org/10.1093/eurheartj/ehag317","authors":["Johan Wouter Jukema","Nicolaas J Van Neer","Michael Szarek","Christa Cobbaert","Vera A Bittner","Markus Schwertfeger","Deepak L Bhatt","Sergio Fazio","Shaun G Goodman","Robert A Harrington","Irena Stevanovic","Harvey D White","Philippe Gabriel Steg","Gregory G Schwartz"],"significance":7,"published":"2026-05-29","source_date":"2026-05-26","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"Post-hoc analysis of ODYSSEY OUTCOMES (n=11,817 patients with recent acute coronary syndrome, all on optimized statin therapy). In models adjusted for each other, treatment assignment, and clinical characteristics, hsCRP independently predicted MACE (p<0.0001) while IL-6 did not; both independently predicted all-cause death. When dichotomised (hsCRP ≥2 mg/L, IL-6 ≥5 pg/ml), risks of MACE and death were elevated only when both markers were elevated. hsCRP conveys inflammatory residual-risk information beyond IL-6 — together they provide a more complete picture.","created":"2026-07-03T10:32:58Z","updated":"2026-07-03T13:31:53Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Post-hoc analyse van de ODYSSEY OUTCOMES-studie (n=11.817 patiënten na acuut coronair syndroom, allen op optimale statinetherapie). In modellen gecorrigeerd voor elkaar, behandelingstoewijzing en klinische kenmerken voorspelde hsCRP onafhankelijk MACE (p<0,0001), terwijl IL-6 dat niet deed; beide markers voorspelden onafhankelijk overlijden. Bij dichotomisering (hsCRP ≥2 mg/L, IL-6 ≥5 pg/ml) was het risico op MACE en sterfte alleen significant verhoogd wanneer beide markers verhoogd waren. hsCRP draagt inflammatoir restrisico-informatie bij bovenop IL-6 — beide samen leveren een vollediger beeld.","abstract_original":"BACKGROUND AND AIMS: After acute coronary syndrome (ACS), high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) levels have been associated with risk of major adverse cardiovascular events (MACE). Whether the prognostic information provided by hsCRP and IL-6 is independent and complementary after ACS is unclear. METHODS: The ODYSSEY OUTCOMES trial compared alirocumab with placebo in post-ACS patients on optimized statin therapy. In post hoc analyses, the relation between log-transformed hsCRP and IL-6 levels and risk of MACE and all-cause death was assessed in proportional hazards models. RESULTS: A total of 11 817 patients had baseline hsCRP and IL-6 data; 1306 had a MACE primary endpoint and 458 died. Median hsCRP, IL-6, and low-density lipoprotein cholesterol (LDL-C) were 1.54 mg/L, 5.00 pg/ml, and 86 mg/dl, respectively. hsCRP and IL-6 had moderate correlation (r = 0.52). In models for one biomarker adjusted for the other biomarker, treatment assignment, age, sex, diabetes, LDL-C, and time since index ACS, hsCRP was a significant independent predictor of MACE (P < .0001) and IL-6 was not (P = .21); both independently predicted death (P < .0001 for hsCRP and P = .0003 for IL-6). Relationships did not depend on treatment (all Pinteraction > .25). When dichotomized at 2 mg/L (hsCRP) and 5 pg/ml (IL-6), risks of MACE and death were significantly elevated when both, but not when one marker was elevated. CONCLUSIONS: In patients with recent ACS, hsCRP independently predicted MACE, while both hsCRP and IL-6 predicted death. Together, the two markers provided complementary prognostic information. hsCRP conveys independent information on inflammatory risk beyond that provided by IL-6."}